Journal of nutritional & environmental medicine最新文献

{"title":"The History of Man in Four Diets","authors":"Damien Downing Mbbs","doi":"10.1080/13590840310001619432","DOIUrl":"https://doi.org/10.1080/13590840310001619432","url":null,"abstract":"","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"139-141"},"PeriodicalIF":0.0,"publicationDate":"2003-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13590840310001619432","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59776567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"What Actually was the Stone Age Diet","authors":"J. Gowlett","doi":"10.1080/13590840310001619338","DOIUrl":"https://doi.org/10.1080/13590840310001619338","url":null,"abstract":"Purpose: In the last few years there has been considerable talk of the ‘Stone Age diet’ as an attractive alternative to the ‘modern’ diet. The underlying idea is that recent distortions of diet are likely to be harmful and that, if we can recover a primeval diet, we will live in closer harmony with our digestive systems and their evolutionary biochemistry. This paper aims to evaluate that set of ideas rigorously in relation to the extensive and sometimes detailed records of the past.Design: Comparative and direct palaeoanthropology and archaeology.Methodology: To review evidence of the comparative picture established by the nearest living relations of hominids (extant apes), and of the deep view given by the fossil records and archaeological evidence.Results: The broad outline of the evolutionary record is becoming increasingly clear: human ancestors diverged from the last common ape ancestor about 8–10 million years ago. Since then major stages of dietary evolution can be traced, involving the incorporat...","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"143-147"},"PeriodicalIF":0.0,"publicationDate":"2003-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13590840310001619338","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59775825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary Restriction: Metabolic Shifting for Cardiac Health","authors":"L. Faine, A. Cicogna, Y. S. Diniz, J. A. Almeida, R. C. Burneiko, H. Rodrigues, E. Novelli","doi":"10.1080/135908403100009501","DOIUrl":"https://doi.org/10.1080/135908403100009501","url":null,"abstract":"Purpose: To determine the effect of dietary restriction on metabolic pathways and the relationship of the metabolic shifting on antioxidant enzymes in cardiac tissue. Design: Randomized, controlled study. Male rats at 60 days old were randomly divided into four groups. Materials and Methods: The rats of control groups C30 and C60 were given free access to the diet over 30 and 60 days. The rats of the DR30 group were fed 60% of the chow consumed by the control groups over 30 days. The animals of the DR60 group ate 60% of the amount consumed by the C60 group over 60 days. Serum was used for total protein, lactate dehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate aminotransferase (AST). Protein, glycogen, total lipids, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), LDH, AST and ALT were determined in cardiac tissue. Results: Dietary restriction induced diminished serum and cardiac LDH activities. AST activities were lower in the serum and cardiac muscle of the DR60 animals. Diet...","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"23-29"},"PeriodicalIF":0.0,"publicationDate":"2003-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/135908403100009501","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59775928","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between Symptoms and Gas Production in Lactose Intolerant Subjects. Can Symptoms Predict a Diagnosis of Lactose Intolerance","authors":"M. Bianchi, M. Tarquini, M. Koch, L. Capurso","doi":"10.1080/1359084031000094995","DOIUrl":"https://doi.org/10.1080/1359084031000094995","url":null,"abstract":"Purpose: To correlate intestinal gas production with the intensity of symptoms experienced during a lactose breath test (LBT) and to evaluate the value of different symptoms in lactose malabsorption diagnosis as assessed by LBT, considered as the gold standard. Design: A statistical correlation between symptoms and gas production, and the prevalence of symptoms in consecutive patients screened for lactose malabsorption. Materials and Methods: All symptoms and their intensity during a 5 hour breath test after a 20 g oral lactose dose were recorded in 214 patients. A symptom score was calculated and correlated to the gases measured in expired air. Results: The most frequently experienced symptoms were: bloating in 70.3% of patients with a pathological breath test and in 22.3% of patients with a normal breath test ( p < 0.0005, odds ratio = 7.7); abdominal pain in 34.7% of patients with a pathological breath test and in 18.7% of patients with a normal breath test ( p = 0.009, odds ratio = 2.7); headache in 1...","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"5-11"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/1359084031000094995","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59775423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Viral Pathogens and Severe Acute Respiratory Syndrome: Oligodynamic Ag+ for Direct Immune Intervention","authors":"E. Rentz","doi":"10.1080/13590840310001594061","DOIUrl":"https://doi.org/10.1080/13590840310001594061","url":null,"abstract":"This retrospective study of silver-based therapeutics briefly reviews their history, and then explores the modern application of charged silver particles, especially as an antiviral agent. The recent outbreak of severe acute respiratory syndrome (SARS) suggests this is timely. Medical literature shows that a variety of viruses have been successfully treated with silverbased drugs. However, ‘silver salts’ and/or inferior silver preparations lack the bio-availability, active silver content and safety needed to be effective. State-of-the-art, electrolytically produced ‘oligodynamic’ Ag 1 , however, offers distinct advantages and versatility of use over older and cruder formulations. Possessing much smaller, subnanometer-sized particles, greater electrical potential and lower concentrations, it is more bio-available than other formulations. Efficacy against the SARS-related coronavirus, for example, may be enhanced when nebulized Ag 1 is inhaled. This should achieve swift reduction of viral loads, especially in the early stages. Moreover, there is no known toxicity for Oligodynamic Ag 1 in humans. The only known mechanism of resistance also appears to play no role notwithstanding the mutability of the coronavirus. Therefore no functional barrier to the virotoxic effects of oligodynamic Ag 1 may be expected regardless of the rapidity or variety of mutations.","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"109-118"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13590840310001594061","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59775668","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Randomized, Double-blind, Placebo-controlled Trial of Coenzyme Q10 in Patients with End-stage Renal Failure","authors":"Ram B. Singh, Adarsh Kumar, M. A. Niaz, R. Singh, S. Gujrati, V. Singh, Mandavi Singh, U. P. Singh, C. Taneja, S. Rastogi","doi":"10.1080/1359084031000095002","DOIUrl":"https://doi.org/10.1080/1359084031000095002","url":null,"abstract":"Background: Free radical damage in conjunction with antioxidant deficiency has been observed in patients with chronic renal failure. In this larger study, we report whether treatment with antioxidant coenzyme Q10 can decrease progression or reverse chronic renal dysfunction and delay the need for dialysis. Design: A randomized, double-blind, placebo-controlled trial of coenzyme Q10 vs. placebo for a period of 12 weeks. Subjects and Methods: All patients with proven chronic renal failure with a history of declining renal function for at least the last 12 weeks were stratified into haemodialysis or no dialysis and blindly randomly divided into coenzyme Q10 ( n = 48) and control ( n = 49) subgroups with the help of computer-generated numbers. Results: Both coenzyme Q groups showed a significant decline in serum creatinine, blood urea nitrogen and a significant increase in creatinine clearance and urine output compared with the placebo groups on dialysis and no dialysis over the 12 weeks of the trial, whereas...","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"13-22"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/1359084031000095002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59775749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Successful Immunotherapy of Acute Viral Infections with a Virus Vaccine","authors":"Joseph Miller","doi":"10.1080/1359084031000095020","DOIUrl":"https://doi.org/10.1080/1359084031000095020","url":null,"abstract":"Since 1968, I have been providing relief in 30 min for patients with acute influenza, as well as for patients with all five types of herpes virus infection seen in my practice. Relief occurs more rapidly than from any antibiotic or anti-viral treatment available. This remarkable response has been obtained by subcutaneously injecting a small skin test determined dose of ordinary influenza virus vaccine. The rapid relief response to influenza virus vaccine constitutes the first specific and rapidly effective anti-viral treatment for any established virus infection. It is unusually safe, rapidly effective, globally available, broadly applicable, and very economical. Because there are 21 vaccines available now, and more to come, this could be the discovery that opens the door to a new era of rapid relief dose therapy with many vaccines. It is important that this be confirmed scientifically. Influenza and herpes virus infections cause much pain, suffering and death world-wide. No comparable therapy is available for any of these infections. Influenza kills thousands of people every year, and some world-wide epidemics (pandemics) have killed millions. Herpes viruses can cause painful fever blisters, eye-destroying ocular herpes, newborn-killing genital herpes, the severe pain of shingles, and the many debilitations and dangers of mononucleosis and chickenpox. Herpes viruses are oncogenic, i.e. they have a tendency to change normal cells into cancer cells. Several cancers, including Hodgkin’s disease, multiple myeloma, and Kaposi’s sarcoma, have been recently reported by many respected investigators to probably be induced by herpes viruses. Is it possible that the incidence of these cancers could be decreased by early treatment of the herpes virus before it has had an opportunity to induce malignant change? This clinical finding has revealed the existence of a simple means of calling into action a rapidly effective diseasefighting mechanism that has not been known or utilized until now. Learning the molecular mechanism of this response could lead to new knowledge about human immunology and bring relief to many patients for whom little relief has been hitherto available. If the small double-blind studies now under way confirm my clinical observations, they could lead to many larger studies and the potential for benefits in numerous additional diseases.","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"31-47"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/1359084031000095020","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59776048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"B-group Vitamins Reduce Plasma Homocysteine Concentration in Patients with Type II Diabetes Mellitus and Normal Basal Homocysteine","authors":"Y. Levy, Y. Yeromenko, R. Levy, I. Friedrich, L. Lavie","doi":"10.1080/13590840310001594043","DOIUrl":"https://doi.org/10.1080/13590840310001594043","url":null,"abstract":"Purpose: High total plasma homocysteine (tHcy) is an independent risk factor for premature cardiovascular disease/mortality in the general population. tHcy has not been well defined as a risk factor in patients with diabetes mellitus (DM) and, therefore, we sought to investigate tHcy and its response to B-group vitamins in patients with DM. Design: Randomized placebo-controlled intervention study. Patients and Methods: Thirty patients with type II DM, aged 60±10 years (range 42-77 years) were compared with 17 age-matched (range 45-69 years) normoglycaemic subjects. Thereafter, the patients were randomly assigned to either B vitamin (B6, folic acid and B12) (n=18) or placebo (n=12) groups for 4 weeks. tHcy was measured using an amino acid analyzer. Results: Compared with the normoglycaemic patients, there were no differences in respect to tHcy, B12, plasma and erythrocyte (RBC) folate in patients with DM. In the B vitamin treatment group, plasma and RBC folate increased from 9.3±4.1 and 395±188 ng ml−1 to ...","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"79-85"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13590840310001594043","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59775632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dr Keith Kenneth Eaton LRCP, LRCS, LRFPS. Retiring President: British Society for Allergy, Environmental & Nutritional Medicine","authors":"D. Freed","doi":"10.1080/13590841031000095048","DOIUrl":"https://doi.org/10.1080/13590841031000095048","url":null,"abstract":"","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"55-58"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13590841031000095048","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59781229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The European Union Directives--How They Impact Innovation in Nutritional Medicine","authors":"R. Verkerk","doi":"10.1080/13590840310001594089","DOIUrl":"https://doi.org/10.1080/13590840310001594089","url":null,"abstract":"","PeriodicalId":88013,"journal":{"name":"Journal of nutritional & environmental medicine","volume":"13 1","pages":"75-77"},"PeriodicalIF":0.0,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/13590840310001594089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"59775706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}